- Stocks
- Pharma & Healthcare
- Bharat Immuno
Bharat Immuno share price
NSE: BIBCLPharma & HealthcareBiotechnology
Bharat Immuno at a glance
With a market capitalisation of ₹75 Cr, it ranks 2823rd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Biotechnology.
Its return on equity was −19.4% in FY23. Promoters held 59.25% of the company as of 31 Mar 2024.
Key numbers
- Market cap
- ₹75 CrRank 2823 on NSE
- Price to book
- 1.09×FY23
- EPS (TTM)
- −₹4.27to Q2 FY24
- ROE
- −19.4%FY23
- ROCE
- −16.8%FY23
- Debt to equity
- 0.8FY23
- Net profit margin
- −38.2%FY23
- Book value / share
- ₹20.33FY23
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Bharat Immuno quarterly results
| Quarter | Q3 FY22 | Q4 FY22 | Q1 FY23 | Q2 FY23 | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹17 Cr | ₹22 Cr | ₹10 Cr | ₹26 Cr | — | ₹8 Cr | — | — |
| Revenue YoY | −30.8% | +41.1% | −26.3% | +7.2% | — | −65.3% | — | — |
| Net profit | −₹0 Cr | −₹1 Cr | −₹5 Cr | −₹3 Cr | −₹5 Cr | −₹4 Cr | −₹5 Cr | −₹5 Cr |
| Net profit YoY | — | — | −359.1% | — | — | — | — | — |
| Net margin | −1.9% | −4.5% | −47.7% | −11.6% | — | −56.1% | — | — |
| EPS | −₹0.08 | −₹0.23 | −₹1.16 | −₹0.71 | −₹1.08 | −₹0.99 | −₹1.06 | −₹1.14 |
Bharat Immuno financials
| Item | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 |
|---|---|---|---|---|---|---|
| Revenue | ₹35 Cr | ₹84 Cr | ₹67 Cr | ₹85 Cr | ₹78 Cr | ₹45 Cr |
| Operating profit | −₹8 Cr | −₹7 Cr | −₹14 Cr | −₹24 Cr | −₹10 Cr | −₹23 Cr |
| Net profit | −₹4 Cr | −₹6 Cr | −₹10 Cr | −₹18 Cr | −₹9 Cr | −₹17 Cr |
| EPS (₹) | −₹0.99 | −₹1.57 | −₹2.36 | −₹4.19 | −₹2.03 | −₹3.95 |
| Cash from operations | ₹0 Cr | −₹32 Cr | ₹34 Cr | ₹34 Cr | −₹42 Cr | ₹11 Cr |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹38 Cr | ₹31 Cr | ₹20 Cr | ₹34 Cr | ₹105 Cr | ₹88 Cr |
Bharat Immuno shareholding pattern
| Holder | 31 Dec 2022 | 31 Mar 2023 | 30 Jun 2023 | 30 Sep 2023 | 31 Dec 2023 | 31 Mar 2024 |
|---|---|---|---|---|---|---|
| Promoters | 59.25% | 59.25% | 59.25% | 59.25% | 59.25% | 59.25% |
| Non-institutions | 40.75% | 40.75% | 40.75% | 40.75% | 40.75% | 40.75% |
Bharat Immuno vs peers
The listed Pharma & Healthcare companies nearest to Bharat Immuno by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| MDRCModern Diagnost | — | — | — | ₹81 Cr | — | — |
| METSLMaestros Elect | — | — | — | ₹76 Cr | — | — |
| BIBCLBharat Immuno | — | — | — | ₹75 Cr | — | — |
| SOURCENTRLSource Natural | — | — | — | ₹70 Cr | — | — |
| APLAsston Pharma | — | — | — | ₹69 Cr | — | — |
| FERVENTSYNFervent Synergi | — | — | — | ₹68 Cr | — | — |
| SUNLOCSunil Health | ₹65.00 | 0.00% | — | ₹67 Cr | 16.6 | — |
Ask anything about Bharat Immuno
Pivot answers on the live chart with evidence you can check, and tests strategies against BIBCL's own history. Try: “Why has BIBCL moved over the last three months?” · “Backtest a 50-day moving-average crossover on BIBCL over five years” · “Compare BIBCL with MDRC on margins and valuation”
Frequently asked questions about Bharat Immuno
What is the market cap of Bharat Immuno?
Bharat Immuno's market capitalisation is ₹75 Cr (₹75 Cr) at the 22 Oct 2026 close, ranking 2823rd among the NSE companies Pivot tracks.
What is the ROE and ROCE of Bharat Immuno?
Return on equity was −19.4% in FY23 and return on capital employed was −16.8% in FY23 (standalone figures).
Is Bharat Immuno a debt-free company?
No. Bharat Immuno's debt-to-equity ratio was 0.8 in FY23, with total debt of ₹0 Cr.
What is the shareholding pattern of Bharat Immuno?
As of 31 Mar 2024: promoters 59.25%, non-institutions 40.75%.
Who are Bharat Immuno's competitors?
The listed Pharma & Healthcare companies closest to Bharat Immuno by market cap are Modern Diagnost, Maestros Elect, Source Natural, Asston Pharma, Fervent Synergi and Sunil Health.
Is Bharat Immuno a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Bharat Immuno's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on BIBCL against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with B · all NSE stocks · this page as text